{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:55:42Z","timestamp":1792400142970,"version":"4.4.0"},"reference-count":18,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The combination of pertuzumab and trastuzumab dual HER2 blockade with concomitant curative dose locoregional breast radiotherapy in patients with metastatic breast cancer is an important part of treatment strategy. Methods: This was a retrospective study conducted at the Institut Curie on all patients treated concomitantly with pertuzumab\/trastuzumab and locoregional breast radiotherapy. Toxicity was evaluated according to the NCICTCAEv4.0. Overall survival, progression-free survival and locoregional recurrence-free survival were evaluated in metastatic patients who were initially well controlled by chemotherapy, for whom local treatment was decided by the multidisciplinary team. Results: Fifty-five patients treated between October 2013 and December 2019 were included, with a median follow-up of 4.1 years. The median age was 53 years (range: 28\u201381). All patients received curative dose radiotherapy (RT) concomitantly with pertuzumab and trastuzumab (Pertu\/Trastu). The median radiation dose was 50 Gy. Safety evaluation did not reveal any significant adverse effects, with 3 cases of grade 3 radiodermatitis (5.4%), but no significant gastrointestinal or cardiac toxicity. The mean difference in LVEF before any chemotherapy and after radiotherapy was \u22122.43% (p &lt; 0.01). Conclusions: This study demonstrates that the combination of locoregional breast RT with dual HER2 blockade by Pertu\/Trastu was very well tolerated, suggesting that RT can be safely administered to patients with HER2-positive breast cancer.<\/jats:p>","DOI":"10.3390\/cancers13194790","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T01:59:47Z","timestamp":1632707987000},"page":"4790","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8011-4208","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Aboudaram","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Loap","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syrine Ben","family":"Dhia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2475-1821","authenticated-orcid":false,"given":"Kim","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fourquet","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia","family":"Kirova","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ctrv.2013.09.002","article-title":"A systematic review of dual targeting in HER2-positive breast cancer","volume":"40","author":"Tuxen","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: Receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J."},{"key":"ref_3","first-page":"1165","article-title":"p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor","volume":"9","author":"Hudziak","year":"1989","journal-title":"Mol. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1535-7163.MCT-06-0766","article-title":"Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance","volume":"6","author":"Barok","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_5","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"2012","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","first-page":"CD006242","article-title":"Trastuzumab-containing regimens for metastatic breast cancer","volume":"2014","author":"Balduzzi","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1158\/1078-0432.CCR-14-1268","article-title":"First FDA approval of neoadjuvant therapy for breast cancer: Pertuzumab for the treatment of patients with HER2-positive breast cancer","volume":"20","author":"Wedam","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.canrad.2020.08.035","article-title":"Association du double blocage de HER2 et radioth\u00e9rapie dans la prise en charge du cancer du sein exprimant HER2","volume":"24","author":"Loap","year":"2020","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.radonc.2013.10.038","article-title":"Whole breast radiotherapy in the lateral decubitus position: A dosimetric and clinical solution to decrease the doses to the organs at risk (OAR)","volume":"110","author":"Kirova","year":"2014","journal-title":"Radiother Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.meddos.2011.03.002","article-title":"Simplified field-in-field technique for a large-scale implementation in breast radiation treatment","volume":"37","author":"Kirova","year":"2012","journal-title":"Med. Dosim."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ijrobp.2007.05.007","article-title":"Postmastectomy Electron Beam Chest Wall Irradiation in Women With Breast Cancer: A Clinical Step Toward Conformal Electron Therapy","volume":"69","author":"Kirova","year":"2007","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2007.12.059","article-title":"How to boost the breast tumor bed? A multidisciplinary approach in eight steps","volume":"72","author":"Kirova","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ejso.2014.03.009","article-title":"Plastic surgery for breast conservation therapy: How to define the volume of the tumor bed for the boost?","volume":"40","author":"Furet","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-018-5058-6","article-title":"A real-world study of cardiac events in >\u20093700 patients with HER2-positive early breast cancer treated with trastuzumab: Final analysis of the OHERA study","volume":"174","author":"Lidbrink","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.radonc.2019.12.019","article-title":"Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis","volume":"145","author":"Kirova","year":"2020","journal-title":"Radiother Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1245\/s10434-018-6831-9","article-title":"Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis","volume":"26","author":"Kirova","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4790\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:04:44Z","timestamp":1760166284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":18,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13194790"],"URL":"https:\/\/doi.org\/10.3390\/cancers13194790","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]}}}